Immix Biopharma, INC. (IMMX) — SEC Filings

Overview

Immix Biopharma, INC. (IMMX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a ARS filed on Apr 6, 2026: Immix Biopharma, Inc. filed an Annual Report to Security Holders (ARS) on April 6, 2026, for the period ending December 31, 2025. The company's mailing address is 10573 W. Pico Blvd. #58, Los Angeles, CA 90064, and its business address is 11400 West Olympic Blvd. Suite 200, Los Angeles, CA 90064. Im

Sentiment Summary

Across 31 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 27 neutral, 1 mixed. The dominant filing sentiment for Immix Biopharma, INC. is neutral.

Filing Type Overview

Immix Biopharma, INC. (IMMX) has filed 1 ARS, 13 8-K, 1 S-8, 1 424B5, 3 10-K, 6 10-Q, 1 10-K/A, 2 DEFA14A, 2 DEF 14A, 1 SC 13G with the SEC between Feb 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (31)

• Immix Biopharma Files Annual Report for 2025 — ARS · Apr 6, 2026 Risk: low
  Immix Biopharma, Inc. filed an Annual Report to Security Holders (ARS) on April 6, 2026, for the period ending December 31, 2025. The company's mailing address
• 8-K Filing — 8-K · Mar 30, 2026
• Immix Biopharma Files S-8 for Employee Stock Plans — S-8 · Mar 25, 2026
  Immix Biopharma, Inc. filed an S-8 on March 25, 2026, to register securities for its employee benefit plans. This filing, with accession number 0001493152-26-01
• Immix Biopharma Files 8-K on Material Definitive Agreement — 8-K · Mar 25, 2026
  Immix Biopharma, Inc. filed an 8-K on March 25, 2026, indicating an "Entry into a Material Definitive Agreement" under Item 1.01. While the specific details of
• Immix Biopharma Files 424B5 Prospectus for Potential Offering — 424B5 · Mar 25, 2026
  Immix Biopharma, Inc. filed a 424B5 prospectus on March 25, 2026, indicating a potential offering of securities. This filing, under File No. 333-292665, suggest
• Immix Biopharma's NXC-201 Shows 75% Complete Response in AL Amyloidosis Trial — 10-K · Mar 25, 2026 Risk: high
  Immix Biopharma, Inc. (IMMX) is a clinical-stage biopharmaceutical company focused on CAR-T cell therapy for AL Amyloidosis and other serious diseases. Their le
• 8-K Filing — 8-K · Dec 8, 2025
• Immix Biopharma Files 8-K: Corporate Details Updated — 8-K · Nov 26, 2025 Risk: low
  Immix Biopharma, Inc. filed an 8-K on November 26, 2025, reporting on other events and financial statements. The filing details the company's principal executiv
• Immix Biopharma's Losses Widen Amid Rising R&D Costs — 10-Q · Nov 7, 2025 Risk: high
  Immix Biopharma, Inc. reported a net loss of $18,750,783 for the nine months ended September 30, 2025, an increase from a net loss of $16,886,309 for the same p
• Immix Biopharma Files 8-K: Agreements, Equity Sales, Officer Changes — 8-K · Sep 8, 2025 Risk: medium
  Immix Biopharma, Inc. filed an 8-K on September 8, 2025, reporting on several key events. These include entering into a material definitive agreement, unregiste
• Immix Biopharma's Q2 Loss Widens Amid R&D Spend — 10-Q · Aug 8, 2025 Risk: high
  Immix Biopharma, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with the prior year periods, as the company remains in th
• Immix Biopharma Reports on Shareholder Vote — 8-K · Jun 23, 2025 Risk: low
  Immix Biopharma, Inc. filed an 8-K on June 23, 2025, reporting on a matter submitted to a vote of its security holders on June 20, 2025. The filing details the
• Immix Biopharma Files 8-K: Material Agreement & Exhibits — 8-K · Jun 3, 2025 Risk: medium
  On June 3, 2025, Immix Biopharma, Inc. filed an 8-K report. The filing indicates an entry into a material definitive agreement and includes financial statements
• Immix Biopharma Files 2024 Annual Report Amendment — 10-K/A · May 19, 2025 Risk: low
  Immix Biopharma, Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2024. The filing, submitted on May 19, 2025, provi
• Immix Biopharma Files Q1 2025 10-Q — 10-Q · May 8, 2025 Risk: medium
  Immix Biopharma, Inc. filed its 10-Q for the period ending March 31, 2025. The company, focused on pharmaceutical preparations, reported financial data for the
• Immix Biopharma Sets June 20th Annual Meeting — DEFA14A · May 5, 2025 Risk: low
  Immix Biopharma, Inc. has filed a Definitive Additional Materials proxy statement (DEFA14A) on May 5, 2025, related to its Annual Meeting of Stockholders schedu
• Immix Biopharma Files Definitive Proxy Statement — DEF 14A · Apr 30, 2025 Risk: low
  Immix Biopharma, Inc. filed its definitive proxy statement (DEF 14A) on April 30, 2025, for the fiscal year ending December 31, 2024. The filing indicates no fe
• 10-K Filing — 10-K · Mar 25, 2025
• Immix Biopharma Files Q3 2024 10-Q — 10-Q · Nov 12, 2024 Risk: medium
  Immix Biopharma, Inc. filed its 10-Q for the period ending September 30, 2024. The company is involved in the pharmaceutical preparations industry, with its pri
• Immix Biopharma Files 10-Q for Q2 2024 — 10-Q · Aug 12, 2024 Risk: medium
  Immix Biopharma, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results for the second quarter and the first six mo
• Immix Biopharma Files 8-K: Corporate Updates — 8-K · Jul 26, 2024 Risk: low
  Immix Biopharma, Inc. filed an 8-K on July 25, 2024, reporting other events and financial statements. The filing details the company's corporate structure, incl
• Immix Biopharma Changes Certifying Accountant — 8-K · Jul 22, 2024 Risk: low
  Immix Biopharma, Inc. filed an 8-K on July 22, 2024, reporting a change in its certifying accountant as of July 17, 2024. The company also included financial st
• Immix Biopharma Announces Corporate Changes and Shareholder Votes — 8-K · Jun 14, 2024 Risk: medium
  Immix Biopharma, Inc. announced on June 11, 2024, a series of significant corporate actions. These include the election of new directors, the appointment of cer
• Immix Biopharma Files Proxy Materials — DEFA14A · May 21, 2024 Risk: low
  Immix Biopharma, Inc. filed a Definitive Additional Materials (DEFA14A) proxy statement on May 21, 2024. The filing concerns materials related to the company's
• Immix Biopharma Reports Unregistered Equity Sales — 8-K · May 20, 2024 Risk: medium
  Immix Biopharma, Inc. filed an 8-K on May 20, 2024, reporting unregistered sales of equity securities. The filing also includes other events and financial state
• Immix Biopharma, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 9, 2024 Risk: low
  Immix Biopharma, Inc. (IMMX) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Immix Biopharma, Inc. filed a 10-Q report for the quarterly period end
• Immix Biopharma, Inc. Announces Annual Meeting of Stockholders on June 11, 2024 — DEF 14A · Apr 29, 2024 Risk: low
  Immix Biopharma, Inc. (IMMX) filed a Proxy Statement (DEF 14A) with the SEC on April 29, 2024. Immix Biopharma, Inc. will hold its Annual Meeting of Stockholder
• Immix Biopharma Files 2023 Annual Report on Form 10-K — 10-K · Mar 29, 2024 Risk: medium
  Immix Biopharma, Inc. (IMMX) filed a Annual Report (10-K) with the SEC on March 29, 2024. Immix Biopharma, Inc. filed its 2023 annual report on Form 10-K on Mar
• AIGH Capital Management Takes 5.8% Stake in Immix Biopharma — SC 13G · Feb 7, 2024
  AIGH Capital Management, LLC, a Maryland-based entity, has reported beneficial ownership of 1,455,000 shares of Immix Biopharma, Inc. common stock as of Februar
• IMMX Files 8-K on Material Definitive Agreement; Details Undisclosed — 8-K · Feb 6, 2024
  Immix Biopharma, Inc. filed an 8-K on February 6, 2024, to report an "Entry into a Material Definitive Agreement" and "Other Events." While the filing indicates
• Immix Biopharma Files 8-K on Feb 5, Confirms Nasdaq Listing — 8-K · Feb 5, 2024
  Immix Biopharma, Inc. filed an 8-K on February 5, 2024, under the 'Other Events' category, indicating a routine update or disclosure that doesn't fall under spe

Risk Profile

Risk Assessment: Of IMMX's 22 recent filings, 3 were flagged as high-risk, 8 as medium-risk, and 11 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Immix Biopharma, INC.'s most recent 10-K filing (Mar 25, 2026):

• Revenue: $0
• Net Income: -$34,136,000
• EPS: N/A
• Debt-to-Equity: 0.0
• Cash Position: $10,211,000
• Operating Margin: N/A
• Total Assets: $17,888,000
• Total Debt: $0

Key Executives

• Heather Landau, MD

Industry Context

The CAR-T cell therapy market is a rapidly evolving and highly competitive segment of the biopharmaceutical industry. Companies are focused on developing treatments for various cancers and rare diseases, with significant investment in research and development. Key trends include expanding indications, improving safety profiles, and reducing manufacturing costs. Immix Biopharma operates in this dynamic landscape, aiming to carve out a niche with its NXC-201 candidate for AL amyloidosis.

Top Tags

pharmaceuticals (4) · corporate-governance (4) · material-agreement (4) · 10-Q (4) · biopharma (3) · financials (3) · proxy-statement (3) · annual-report (2) · dilution (2) · corporate-action (2)

Key Numbers

• Period of Report: 2025-12-31 — The end date for the reporting period covered by the ARS.
• Filing Date: 2026-04-06 — The date the ARS was officially filed with the SEC.
• Aggregate market value of non-affiliate common equity: $35,708,995 — as of June 30, 2025, indicating a relatively small market cap for a clinical-stage company
• Complete response rate for NXC-201: 75% — observed in 15 out of 20 patients in NEXICART-2 trial as of November 13, 2025
• Expected patient enrollment for NEXICART-2: 40 — U.S. Phase 1b/2 clinical trial
• Date of positive interim data announcement: 2025-12 — for NEXICART-2 clinical trial
• Date of Breakthrough Therapy designation: 2026-01 — awarded by FDA for NXC-201
• Remaining grant amount: $1.8 million — from California Institute for Regenerative Medicine, which Immix may not receive
• Net Loss: $18.75M — Increased from $16.89M in 2024 for the nine-month period, indicating widening losses.
• Cash and Cash Equivalents: $15.95M — Decreased from $17.68M at year-end 2024, showing a decline in liquidity.
• Total Operating Expenses: $19.06M — Increased from $17.69M in 2024 for the nine-month period, driven by R&D and G&A.
• Research and Development Expenses: $10.53M — Key driver of increased operating expenses for the nine-month period.
• Proceeds from Stock Sales: $11.88M — Capital raised through common stock sales, partially offsetting cash burn.
• Net Cash Used in Operating Activities: $12.90M — Significant cash outflow from core operations for the nine-month period.
• Common Shares Outstanding: 33,577,873 — As of November 5, 2025, indicating potential for further dilution.

Frequently Asked Questions